# The effect of the Flemish breast cancer screening program on breast cancer-specific mortality: A case-referent study

Source: https://onco.cc/key-papers/paper-de-troeyer-flemish-breast-screening-mortality-2023/  
OnCo record `paper-de-troeyer-flemish-breast-screening-mortality-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Belgian Cancer Registry study found that women who took part in the Flemish breast screening programme had about half the risk of dying of breast cancer of women who did not, even where many women are screened privately.

## Summary

A case-referent study of the population-based mammography screening programme introduced in Flanders in 2001, in a setting with high levels of opportunistic screening. It compared participation in the programme in the four years before (pseudo)diagnosis between women who died of breast cancer from 2005 to 2017 and randomly selected referents, using multiple logistic regression adjusted for individual socio-economic position and calendar year of diagnosis, stratified by age, with sensitivity analyses and a correction for self-selection.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Cancer Epidemiology
- Year: 2023
- DOI: 10.1016/j.canep.2022.102320
- Authors: De Troeyer K, Silversmit G, Rosskamp M, Truyen I, Van Herck K, Goossens MM, et al.
- Findings: 1,571 cases and 6,284 referents were identified.; Participants had a 51% lower risk of breast cancer-specific death than non-participants (adjusted odds ratio 0.49, 95% CI 0.44 to 0.55).; Correction for self-selection bias reduced the effect size, but the estimate remained significant.
- What it means: Even where many women already have mammograms outside the programme, taking part in the organised programme was associated with a substantially lower risk of dying of breast cancer. The authors say this should be weighed against the harms of screening, including overdiagnosis and overtreatment.
- Caveats: An observational case-referent design, not a randomised trial; self-selection can only be partly corrected.; This record summarises the abstract.

## Sources

- Cancer Epidemiology 2023: https://doi.org/10.1016/j.canep.2022.102320
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36608495/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/)
- institutions: [Belgian Cancer Registry (Stichting Kankerregister / Fondation Registre du Cancer)](https://onco.cc/institutions/belgian-cancer-registry/), [Centrum voor Kankeropsporing (CvKO)](https://onco.cc/institutions/centrum-voor-kankeropsporing/)

---
JSON: https://onco.cc/api/v1/entities/paper-de-troeyer-flemish-breast-screening-mortality-2023.json